Form 13G Solid Biosciences Inc. For: 5 May
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Solid Biosciences LLC (SLDB)
The Solid Biosciences share price today is 7.195, view NASDAQ SLDB stock exchange data. Track the latest Solid Biosciences share price with real-time updates on SLDB stock performance including market cap, day range, 52-week range and dividend yield. Access SLDB charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.860
7.290
52 wk Range
2.410
8.866
SLDB is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
6.8607.290
52 wk Range
2.4108.866
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SLDB Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
17.077
Upside
+137.34%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
3 analysts have revised their earnings upwards for the upcoming period
- Form 8K Solid Biosciences LLC For: 10 April
- Investing.com
- Form 13G Solid Biosciences Inc. For: 5 May
- Investing.com
- Form DEF 14A SOLID BIOSCIENCES INC. For: 23 April
- Investing.com
- Form PRE 14A SOLID BIOSCIENCES INC. For: 10 April
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
13 Buy
0 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 17.077
(+137.34% Upside)
Solid Biosciences LLC SWOT Analysis
Gene Therapy Pionee | Solid Biosciences leads in DMD treatment with SGT-003, showing 100% microdystrophin expression and favorable safety profile in early trials |
Pipeline Expansion | Explore Solid's strategic move into Friedreich's ataxia and CPVT, diversifying its portfolio and tapping into new market opportunities |
Financial Outlook | Delve into Solid's $200M capital raise, extending cash runway to 2027, while analysts set price targets ranging from $10 to $20 |
Market Challenges | Learn how Solid navigates a competitive landscape, regulatory hurdles, and potential safety concerns in the evolving gene therapy field |
Earnings
Latest Release
19-03-2026
EPS / Forecast
-0.53 / -0.62
Revenue / Forecast
-- / --
Compare SLDB to Peers and Sector
Metrics to compare | SLDB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSLDBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.1x | −3.8x | −0.5x | |
PEG Ratio | −0.11 | −0.09 | 0.00 | |
Price/Book | 3.9x | 2.4x | 2.6x | |
Price / LTM Sales | - | 10.1x | 3.2x | |
Upside (Analyst Target) | 131.9% | 82.3% | 47.8% | |
Fair Value Upside | Unlock | 7.9% | 5.9% | Unlock |
Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company’s lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Solid Biosciences (SLDB) Share Price Today?
The Solid Biosciences share price today is 7.195.
What is the current Solid Biosciences (SLDB) share price and day range?
As of 06-05-2026, the Solid Biosciences share price is 7.195, with a previous close of 6.900. The share price has ranged from 6.860 to 7.290 today, while the 52-week range spans from 2.410 to 8.866.
What Is the Solid Biosciences Market Cap?
As of today, Solid Biosciences market cap is 707.100M.
What Is the Solid Biosciences (SLDB) Share Price Target?
The average 12-month share price target for Solid Biosciences is 17.077, with a high estimate of 26 and a low estimate of 12. 13 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +137.34% Upside potential.
What Is Solid Biosciences's Earnings Per Share (TTM)?
The Solid Biosciences EPS (TTM) is -1.992.
When Is the Next Solid Biosciences Earnings Date?
Solid Biosciences will release its next earnings report on 19-03-2026.
From a Technical Analysis Perspective, Is SLDB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
What Stock Exchange Does Solid Biosciences Trade On?
Solid Biosciences is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Solid Biosciences?
The stock symbol for Solid Biosciences is "SLDB."
How Many Times Has Solid Biosciences Stock Split?
Solid Biosciences has split 1 times.
How Many Employees Does Solid Biosciences Have?
Solid Biosciences has 121 employees.
What Is the SLDB Premarket Price?
SLDB's last pre-market stock price is 7.050. The pre-market share volume is 1,18,740.000, and the stock has changed by 0.150, or 2.170%.
What Is the SLDB After Hours Price?
SLDB's last after hours stock price is 7.320, the stock has changed by 0.120, or 1.670%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.